US OptionsDetailed Quotes
ESPR241220C500
- 0.00
- 0.000.00%
15min DelayClose Dec 13 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest0.50Strike Price0.00Turnover771.28%IV-77.78%PremiumDec 20, 2024Expiry Date1.75Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9791Delta0.0230Gamma1.27Leverage Ratio-0.0090Theta0.0001Rho1.24Eff Leverage0.0001Vega
Esperion Therapeutics Stock Discussion
gone for good ? 😢
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Esperion Therapeutics (NASDAQ: ESPR) has entered into a licensing agreement with Neopharm Israel for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Israel. The agreement includes an upfront payment, near-term milestone payments, and tiered royalties on product sales.
Under the agreement terms, Neopharm will rece...
1 min ago
Esperion Partners With Neopharm to Commercialize Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe) in Israel! Esperion Therapeutics Inc: Under Terms of Agreement, Esperion Will Receive an Upfront and Near-Term Milestone Payments
No comment yet